September 12, 2011

Initiation of Lantus leads to better glycemic control at similar weight gain versus other comparators in patients with Type 2 Diabetes

- Weight gain was lowest in patients with baseline A1C below 8 percent and in patients 65 years and older -
- Pooled Analysis Presented at European Association for the Study of Diabetes (EASD) 47th Annual Meeting -

 

Initiation of Lantus leads to better glycemic control at similar weight gain versus other comparators in patients with Type 2 Diabetes
- Weight gain was lowest in patients with baseline A1C below 8 percent and in patients 65 years and older -
- Pooled Analysis Presented at European Association for the Study of Diabetes (EASD) 47th Annual Meeting -

Paris, France – September 12, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data that demonstrates that initiating Lantus® (insulin glargine [rDNA origin] injection) in type 2 diabetes patients leads to better glycemic control and comparable and modest weight gain versus a comparator group consisting of other insulins, oral antidiabetics (OADs) and dietary changes. The lowest weight gain was seen in patients initiating treatment with baseline A1c levels below eight percent and in patients aged 65 and older. This data is being presented at the European Association for the Study of Diabetes (EASD) 47th Annual Meeting in Lisbon, Portugal.1